Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT
ISRCTN52028580Phase 4Completed
- Sponsor
- University of Liverpool
- Start
- Oct 2017
- Modality
- Peptides, Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide + dapagliflozin, Dapagliflozin alone and Placebo control (3 arms). Started Oct 2017; status: completed.
02
Drugs
exenatidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN52028580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52028580.